Aurinia Pharmaceuticals (AUPH) Tops Q2 EPS by 10c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 EPS of ($0.08), $0.10 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $41.49 million versus the consensus estimate of $37.9 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
• Ennis (EBF) Reports In-Line Q1 EPS